logo
Select company
Select metric
$ 0.11EBITDA per Share
VS
Market
36
Sector
76
Industry
90
History
90
$ 8.3Close
$ 6.41 - $ 16.8 52-Week Range
Ticker Information

Ticker

GYRE

Company Name

GYRE THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

GYRE THERAPEUTICS INC - EBITDA per Share Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

GYRE - EBITDAPS Historical data
DateEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)EBITDA per ShareShare FactorWeighted Average Shares
6/30/2025$ 9.86M$ 0.11189.12M
3/31/2025$ 13.36M$ 0.15186.42M
12/31/2024$ 19.63M$ 0.23185.09M
9/30/2024$ -60.39M$ -0.71185.64M
6/30/2024$ -64.75M$ -0.76185.5M
3/31/2024$ -72.66M$ -0.87183.27M
12/31/2023$ -82.99M$ -1.26165.83M
9/30/2023$ -43.86M$ -17.3312.53M
6/30/2023$ -47.13M$ -18.712.52M
3/31/2023$ 7.04M$ 2.812.52M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • GYRE THERAPEUTICS INC's latest trailing twelve months (TTM) EBITDAPS stands at $ -34.53.
  • Over the past 5 years, GYRE THERAPEUTICS INC's average EBITDAPS has been $ -15.74.
  • The median EBITDAPS for GYRE THERAPEUTICS INC during this period was $ -3.75
  • GYRE THERAPEUTICS INC reached its highest EBITDAPS over the past 5 years at $ 5.82.
  • The lowest EBITDAPS recorded by GYRE THERAPEUTICS INC in the same timeframe $ -43.88

GYRE THERAPEUTICS INC's EBITDAPS vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDAPS Benchmarks
CompanyEBITDAPS
PHAT : PHATHOM PHARMACEUTICALS INC $ -3.54NAGE : NIAGEN BIOSCIENCE INC $ 0.25ANAB : ANAPTYSBIO INC $ -4.52TBPH : THERAVANCE BIOPHARMA INC $ 0.96URGN : UROGEN PHARMA LTD $ -2.81CRMD : CORMEDIX INC $ 0.77NRIX : NURIX THERAPEUTICS INC $ -2.68ZVRA : ZEVRA THERAPEUTICS INC $ 0.67KURA : KURA ONCOLOGY INC $ -2.2SAGE : SAGE THERAPEUTICS INC $ -4.8

Similar metrics to Shares WA:

Definition of EBITDA per Share

[Calculation] The amount of earnings before interest, taxes, depreciation, and amortization attributed to each share, calculated as [EBITDA] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
EBITDA / (Shares WA * Share Factor)
(=) EBITDAPS EBITDAPS for GYRE THERAPEUTICS INC is calculated as follows: EBITDA [ $ -50.82M ] / (Shares WA [ 1.47M ] * Share Factor [ 1 ])
(=) EBITDAPS [ $ -34.53 ]

GYRE - EBITDA per Share, Last 5 years

$ -43.88

Minimum

Dec 31, 2020

$ 5.82

Maximum

Sep 30, 2022

$ -15.74

Average

$ -3.75

Median

EBITDAPS Benchmark Analysis

 The chart above depicts the distribution of EBITDAPS for companies in the Total Stock Market. The average EBITDAPS of the companies is $ 2.01 with a standard deviation of $ 4.26.
The following table provides additional summary stats:
EBITDAPS in the Market:
filtered constituents3.78K
min$ -10.86
max$ 13.95
average$ 2.01
median$ 0.99
std$ 4.26